Clinical Trial Update: Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform [Phase 3]

View source ↗

Summary

Phase 3 hemophilia inhibitor trials (INHIBIT platform) were withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Snippet

Sponsor: Margaret Ragni | Conditions: Severe Hemophilia A | Phase 3 | Status: WITHDRAWN